key: cord-0967775-no9ch9nz
authors: Torres, Marcelo D.T.; de Araujo, William R.; de Lima, Lucas F.; Ferreira, André L.; de la Fuente-Nunez, Cesar
title: Low-cost Biosensor for Rapid Detection of SARS-CoV-2 at the Point-of-Care
date: 2021-05-09
journal: Matter
DOI: 10.1016/j.matt.2021.05.003
sha: 0573612e18a320f5badfdcc36910ff27166d4e5e
doc_id: 967775
cord_uid: no9ch9nz

SARS-CoV-2, the virus that causes COVID-19, has killed over 3 million people worldwide. Despite the urgency of the current pandemic, most available diagnostic methods for COVID-19 use RT-PCR to detect nucleic acid sequences specific to SARS-CoV-2. These tests are limited by their requirement of large laboratory space, high reagent costs, multistep sample preparations, and the potential for cross-contamination. Moreover, results usually take hours to days to become available. Therefore, fast, reliable, inexpensive, and scalable point-of-care diagnostics are urgently needed. Here, we describe RAPID 1.0, a simple, handheld, and highly sensitive miniaturized biosensor modified with human receptor angiotensin-converting enzyme-2 (ACE2) that can detect SARS-CoV-2 using 10 μL of sample within 4 minutes through its increased resistance to charge transfer of a redox probe measured by electrochemical impedance spectroscopy. The sensitivity and specificity of RAPID for nasopharyngeal/oropharyngeal swab and saliva samples are 85.3% and 100% and 100% and 86.5%, respectively.

SARS-CoV-2, the virus that causes COVID-19, continues to kill people at a staggering pace 1 , threatening the global economy, healthcare systems, and our lives. Despite the urgency of the pandemic, the high cost of production, lack of scalable technologies, and slow detection time hinder the widespread use of currently available diagnostics. Therefore, low-complexity point- 5 of-care diagnostic tests with a rapid turnaround time are urgently needed.

Here, we describe a simple, inexpensive, and rapid test for the detection of SARS-CoV-2 ( Figure   1a ). RAPID 1.0 (Real-time Accurate Portable Impedimetric Detection prototype 1.0) transforms biochemical information from a specific molecular binding event between the SARS-CoV-2 spike protein (SP) and ACE2 into an electrical signal that can easily be detected. 10 RAPID 1.0 (henceforth referred to as RAPID) uses electrochemical impedance spectroscopy (EIS), an electrochemical technique extensively utilized for the characterization of functionalized electrode surfaces and the transduction of biosensors 2, 3 . In our test, the EIS transducer signal reports the selective interaction/binding between the biological receptor immobilized on the electrode surface (i.e., ACE2) and its binding element (i.e., spike protein) 4 . The binding between 15 these two molecules causes a change in interfacial electron transfer kinetics between the redox probe, ferricyanide/ferrocyanide in solution and the conducting electrode sites. This electrochemical change is then detectable by monitoring the charge-transfer resistance (R CT ), the diameter of the semi-arc on the Nyquist plot, which correlates with the number of targets bound to the receptive surface 2 . The selectivity of an EIS biosensor mostly relies on the specificity 20 between the target and the recognizing bioelement immobilized on the electrode surface and its robustness through the designed architecture surfaces to minimize non-specific binding of the analyte or adsorption of other biomolecules in solution.

We designed the electrochemical device to explore the remarkable binding affinity of SARS-CoV-2 spike protein (SP) to ACE2, its receptor in the human body 4, 5 (Figure 2a) . The working 25 electrode (WE), where the (electro)chemical reaction/interaction takes place and is converted to a detectable analytical signal, was functionalized by a drop-casting method. Enzyme immobilization was achieved by cross-linking ACE2 using the bifunctional chemical cross-linker glutaraldehyde (GA) 6 . This dialdehyde reacts mainly with the primary amino groups of proteins, for example, the ε-amino group of lysine residues or the N-terminal group of the protein chain 7 . 30 

We used bovine serum albumin (BSA) to block the electrode's surface after immobilization of ACE2. BSA is a functionally inert protein with a high density of superficial lysine residues that is commonly used for biosensor development 7 .

Using these well-established protocols for bioelectrode development, we first added GA for 1 hour at 37 ºC to fully cover the carbon electrode surface generating a cross-linked polymer that 5 enables the covalent anchoring of ACE2 at 37 ºC for 1.5 hours (Figure 1b) . Next, BSA was added to the surface of the electrode for 30 minutes at 37 ºC to block possible remaining active sites (i.e., working electrode's surface areas that were not functionalized with ACE2) thus preventing nonspecific adsorption to the GA layer by other proteins. We also incorporated an additional functionalization step using a 1.0% Nafion solution ( Figure S2 ) to create a protective 10 polymeric membrane enhancing the robustness of the biosensor 8 . Interestingly, Nafion increased up to 2-fold the sensitivity of the biosensor, particularly when used at a concentration ranging between 1.0% and 1.5% ( Figure S2 ). Given these results, we selected 1.0% Nafion (wt%) for subsequent optimization steps because of its optimal analytical response to low reagent usage ratio 8 . This anionic membrane enables small positively charged species to cross and 15 preconcentrate close to the biosensing surface. The Nafion layer also enhanced the robustness of RAPID by protecting against biofouling of the electrodic surface when exposed to the sample's complex matrix (e.g., proteins, lipids, and other macromolecules present in biological samples) that may interfere with the detection 8,9 .

To ensure that the biological activity of ACE2 was preserved upon immobilization onto the 20 electrode's surface, we evaluated the response of the sensor when exposed to its natural substrate angiotensin II ( Figure S1 ). A sensitive linear response was observed in the range of 1 pg mL -1 to 10 g mL -1 of angiotensin II, demonstrating that our anchoring and stabilization strategies maintained the functionality of ACE2's active sites and revealing that the biosensor architecture did not obstruct ACE2. 25 Next, we characterized the effect of each modifier layer (GA, ACE2, BSA, and Nafion) on the electrochemical response of our modified electrode, recording cyclic voltammetry (CV) and EIS measurements in the presence of 5 mmol L -1 of the redox probe potassium ferricyanide/ferrocyanide (Figures 2b and 2c) . These results demonstrated that the peak current signal of the redox probe decreased when using CV and the resistance to charge transfer 30 J o u r n a l P r e -p r o o f 5 increased after each functionalization step. The decrease in the peak current signal occurs due to the addition of nonconductive materials (e.g., proteins) that block the active sites of the electrodic surface, hindering the kinetics of charge transfer of the redox probe. Our optimized protocol generated the best analytical signal for the detection of SARS-CoV-2 in human biofluid samples (Figure 1a ). It consists of the following 4-steps: 1) modifying the working electrode 5 with the immobilizing agent (GA); 2) covalent attachment of the recognition agent ACE2; 3) addition of the stabilization and active site blocking agent BSA; and 4) incorporating the permselective membrane (Nafion). A detailed protocol describing biosensor preparation, including the production of the screen-printed devices and functionalization, is provided in the Supplemental Appendix. 10 Our test can be performed at room temperature with minimal equipment and reagents, and costs $4.67 to produce [$0.07 to produce the bare electrode, $4.50 to functionalize the electrode with the recognition agent ACE2, and $0.10 to coat the electrode with GA, BSA, and Nafion used ( Figure 1c) ]. The overall cost of RAPID may be further reduced through recombinant production of ACE2 and ACE2 variants 10 . Our technology is also highly scalable, as the electrodes can be 15 rapidly mass-produced by using commercially available screen-printers. One laboratory-sized unit is able to produce 35,000 electrodes daily (1.05 M electrodes/month) and this could scaledup to 10.5 billion electrodes monthly with only 10,000 screen-printers (Table S1 ). These estimates take into account both the time needed to print the electrodes and all functionalization steps (i.e., 1 hour for GA functionalization, 1.5 hours to incorporate ACE2, 0.5 hours for BSA, 20 and 1 hour for Nafion; total of 4 hours). However, it must be noted that these steps can be fully automated into a production line for industrial purposes, drastically reducing time requirements.

We evaluated the incubation time (i.e. time of exposure of the sample to the biosensor to enable sensitive detection), and whether a centrifugation/dilution step was needed to detect SARS-CoV-2 in complex biological samples such as saliva 11 . Next, we built dose-response curves using free 25 spike protein to assess the effect of incubation time ( Figure S4 ), centrifugation ( Figure S3 ), and sample dilution ( Figure S3 ) on the performance of RAPID. Our optimization steps revealed that an additional centrifugation step was not needed ( Figure S3 ) since the use of neat saliva yielded similar results to those obtained using centrifuged samples. These results demonstrated that our approach is robust and can directly use human samples (NP/OP or saliva) without a prior care diagnosis. We selected 2 minutes as the optimal incubation period of the sample on the working electrode's surface for sensitive SARS-CoV-2 detection in samples considering the detectability and analytical frequency of the tests ( Figure S4 ). Our very minimal incubation time requirement (2 minutes) confirms the favorable configuration of the modified electrode that allows rapid interaction kinetics between the SP and immobilized ACE2 [kinetics constant rate 5 of 10 4 M −1 s −1 in its natural environment 4 ]. Overall, RAPID provides a result in 4 minutes (2 minutes of sample incubation + 2 minutes to perform the EIS analysis), which is vastly faster than methods currently available for diagnosing COVID-19 ( Figure 1c ). It is important to note that the total time required to run each blank is an additional 4 minutes. However, we did not take this into account in our testing time calculations because the blanking step can be done 10 before analyzing clinical samples, and we can use the R CT values obtained for the blanks (PBS or VTM) to compare with the patient sample values.

Taking into account the optimal analytical conditions evaluated (Table 1) , we built calibration curves for free SP (Figure 2d , S5a, S5b) and heat-inactivated virus (Figure 2e) using the normalized R CT response, defined by the following equation: 15 where Z is the R CT of the sample and Z 0 is the R CT of the respective blank solution: phosphate buffer saline (PBS), virus transportation medium (VTM), or healthy saliva. The normalization process of R CT aims to correct eventual fluctuations in the sensor operation, such as the temperature at the testing point or variations due to analyst operation. The dose-response curve for the free SP in PBS solution ranged from 1 fg mL -1 to 10 µg mL -1 ( Figure S5a ). A linear 20 concentration range from 10 fg mL -1 to 100 ng mL -1 was obtained (R 2 = 0.993) and limits of detection (LOD) and quantification (LOQ) were calculated as 2.18 fg mL -1 and 7.26 fg mL -1 SP based on signal to noise ratios (S/N=3) and (S/N=10), respectively. We built a dose-response for the free SP in VTM medium at a concentration range from 10 fg mL -1 to 100 pg mL -1 ( Figure   S5b ). A linear concentration range from 10 fg mL -1 to 1 ng mL -1 was obtained (R 2 = 0.995) and 25 limits of detection (LOD) and quantification (LOQ) were calculated as 6.29 fg mL -1 and 20.96 fg mL -1 SP based on the signal to noise ratio (S/N=3) and (S/N=10), respectively. When performed in neat saliva, the calibration curve was built at a concentration ranging from 100 fg mL -1 to 100 ng mL -1 (Figure 2d ). The calculated LOD and LOQ were 1.39 pg mL -1 and 4.63 pg mL -1 , J o u r n a l P r e -p r o o f respectively. The higher LODs obtained in saliva and VTM are consistent with the increased sample complexity compared to PBS solution.

The R CT values of Nyquist plots were extracted by the application of an equivalent circuit ( Figure S6 ). The equivalent circuit comprises two semi-arc regions observed in the Nyquist plots, where the first is a non-defined semi-arc at a high-frequency range due to inhomogeneity 5 or defects in the electrode modification step (during drop-casting functionalization) and

considerably small (R CT ~10 ) 12,13 . The second parallel component of the equivalent circuit comprises an R CT, whose signal intensity was proportional to the logarithm of the SP/virus concentration, and also presented a Warburg element to describe the mass transport (diffusional control). 10 The concentration range of SP detected by our device was 10-1,000 times lower than that reported in previous studies 14, 15 , thus underscoring the sensitivity of our approach. To assess the diagnostic capability of RAPID, we calibrated our biosensor using tittered solutions of inactivated SARS-CoV-2 ranging from 10 1 to 10 6 PFU mL -1 (Figure 2e ). RAPID exhibited high sensitivity presenting a limit of detection (LOD) of 1.16 PFU mL -1 , which corresponds to the Next, we evaluated the stability of RAPID at different temperature storage conditions (25 ºC, 8 ºC, and -20 ºC) over 10 days ( Figure S9 ). Analytical curves were generated with SP at a concentration ranging from 1 pg mL -1 to 1 ng mL -1 and the sensitivity was normalized by the mean value of the three different biosensors used immediately after the functionalization steps.

The biosensors stored at room temperature did not detect the SP after 24 hours due to loss of 5 enzymatic activity ( Figure S9 ). The sensors stored at 8 ºC were stable after 24 hours, but after 48 hours presented decreased sensitivity (around 50% of the initial response) keeping this low sensitivity for 7 days ( Figure S9 ). Biosensors stored at -20 ºC exhibited the most promising results since they were as sensitive as those used right after functionalization even after 96 hours and retained 50% of their sensitivity after 10 days of storage ( Figure S9 ). 10 Next, the performance of RAPID was assessed using both SARS-CoV-2-positive and negative clinical samples from the Hospital of the University of Pennsylvania (HUP) (Table S2 and We also observed that centrifuging the samples did not lead to increased impedimetric detection of the SP ( Figure S3 ). Therefore, the NP/OP and saliva samples were used in VTM and PBS, respectively, following the Food and Drug Administration (FDA) recommendation for regulatory applications. Of note, the detectability of impedimetric measurements after 2 minutes of 30 incubation of the sample on the working electrode's surface was as high as longer incubation J o u r n a l P r e -p r o o f times of 5 and 10 minutes ( Figure S4 ), thus demonstrating RAPID's fast interaction kinetics between the SP and functionalized WE, as discussed above. Thus, we selected 2 minutes of incubation and set as a cut-off value a 10% change in the R CT when compared to the blank solution. Such a cut-off threshold takes into account the LOQ obtained for inactivated virus analysis (Figure 2e ), thus allowing discrimination between SARS-CoV-2 negative and SARS- 5 CoV-2 positive samples (Tables S2 and S3 ).

In blinded tests, we analyzed 139 NP/OP swab samples (in VTM) obtained from patients after heat-inactivation, 109 of which were COVID-19 positive and 30 COVID-19 negative as determined by RT-qPCR and clinical assessment (Table S2 ). RAPID demonstrated high sensitivity, specificity and accuracy for NP/OP (83.5%, 100% and 87.1%, respectively; Table 2) 10 and saliva (100%, 86.5% and 90.0%, respectively; Table 2 ) samples. RAPID missed a single sample, which presented a viral count lower than its LOD (10 -1 RNA copies L -1 ). It is worth noting that although the heat inactivation protocol decreased the response of our biosensor due to the inactivation of SP ( Figure S10 ), the outstanding sensitivity of RAPID (Table 1 ) enabled high detectability (Table 1 ) and hit rate ( Table 2 ). Out of the 12 negative NP/OP swab samples 15 present in our sample set, 100% were confirmed as SARS-CoV-2 negative by RAPID (Table 2 ).

In addition, the highly contagious SARS-CoV-2 UK variant B.1.1.7 was obtained from a government testing site in Philadelphia (Tables 2 and S3 ). RAPID successfully identified this sample as positive with a normalized R CT value of 1.10 (Table S2) , thus underscoring its ability to detect emerging mutant variants of SARS-CoV-2. 20 To evaluate RAPID's diagnostic efficacy in a more complex biological environment, we tested saliva samples from 50 patients (Table S3 ) under the same conditions used for the NP/OP swab samples. The greater complexity of saliva, compared to swab samples, is known to hinder the accurate detection of infectious agents 11,18 . Saliva is a biofluid that is susceptible to large variations in composition depending on different factors such as the ingestion of food and drinks 25 prior (30-60 minutes) to sample collection, which can lead to the dilution of the saliva matrix, and the insertion of exogenous molecular species that may interfere with accurate detection.

Even using highly heterogenous saliva samples, the sensitivity of RAPID remained high (100%), however false positives led to decreased specificity (86.5%), and an accuracy of 90.0% ( Table   2 ). The latter results may be explained by potential interactions between ACE2, which is a 30 J o u r n a l P r e -p r o o f carboxypeptidase and amino acid transporter, and other biomolecules that can be found in neat biofluids, such as regulatory peptides and peptide hormones (e.g., angiotensin, bradykinin, ghrelin, apelin, neurotensin, and dynorphin) 20 . Thus, we believe the performance of RAPID will improve when using fresh saliva samples at the point-of-care. It is worth noting that among the SARS-CoV-2-positive saliva samples, our test identified as positive two samples that had been 5 previously erroneously detected as negative by RT-qPCR, therefore indicating that RAPID may help correctly diagnose COVID-19 in samples previously misdiagnosed by other methods.

Several key analytical features were used to compare the performance of RAPID with respect to other electrochemical methods reported in the literature (Table 3) . Our method provides the highest sensitivity (LOD of 2.8 fg mL -1 ) for the detection of SARS-CoV-2 spike protein with 10 excellent time of detection and overall cost (Table 3) . Additionally, the robustness of RAPID was evaluated in a large clinical sample set (Table S2 and S3), and all results were compared with those obtained by RT-qPCR (Table 2) , thus highlighting the reliability of our method. All experiments described thus far (e.g., detection of SARS-CoV-2 spike protein and clinical samples) were performed using the eChip version of the electrode (e.g., Figure 2 , Table 2 , 15 Figures S2 and S3). After successfully applying the eChip (composed of printed circuit board) to clinical samples (Tables S2 and S3 ) and obtaining robust and sensitive results (Table 1) , we sought to construct an optimized electrode composed of a material that was more accessible and inexpensive to enable scale-up production of RAPID. We selected filter paper as the main component of electrochemical paper-based analytical device (ePAD) as it is easy to handle 20 (maleable), accessible, and inexpensive [paper filter costs $0.50 per 1 m 2 whereas printed circuit board (PCB) costs $40.00 per 1 m 2 ] 21, 22 . We adapted and demonstrated the applicability of ePAD in a portable potentiostat connected to a smart device (Figure 3a) . We used the screenprinting method to fabricate the electrodes and combined wax-printing technology to pattern the electrochemical cell onto the paper filter. Thus, the ePAD is composed of more accessible and 25 low-cost material, enabling scalable manufacturing and on-demand testing at the point-of-care 21, 22 .

In order to enhance the detectability (i.e., the LOD) of RAPID, we added 2.5-fold increased volumes of the modifiers (GA, ACE2, BSA, and Nafion) on the surface of the WE during the fabrication process. This approach allowed higher sensitivity towards the detection of SP, which 30 was used to generate a calibration curve (Figure 3b) . We attribute the enhanced detection (7-fold J o u r n a l P r e -p r o o f increase) of the paper-based version of RAPID compared to the phenolic-based electrode (eChip) to the higher amount of recognition element (ACE2) used on the working electrode's surface.

However, it is worth noting that the eChip version already demonstrated excellent performance at detecting SARS-CoV-2 (Tables 1 and 2 ) and, although its sensitivity can be further increased by using a higher concentration of ACE2 (Figure 3b) , this would increase the cost of the test 5 since recombinant ACE2 accounts for 95% of the final cost of RAPID 1.0 (Figure 1c) .

RAPID presented higher accuracy, specificity, and selectivity than most existing electrochemical methods available for SARS-CoV-2 detection (Table 3) 16 . We also assessed RAPID's specificity in cross-reactivity assays by exposing our sensor to the following seven Table S4 ). We did not detect cross-reactivity events against any of the viruses tested (R CT < 10%) (Table S4) Ethical Statement: 5 This study was performed under the University of Pennsylvania IRB protocol 844145.

The authors declare no competing interests. Note that comparisons were made for a single test of each of the different technologies. Table 1 . Analytical parameters of RAPID 1.0.

Linear concentration range (SP in PBS) 10 fg mL -1 -100 ng mL -1 Linear concentration range (SP in VTM) 10 fg mL -1 -1 ng mL -1

Linear concentration range (SP in saliva) 100 fg mL -1 -100 ng mL 

Further information and requests for resources should be directed to and will be fulfilled by the lead contact, Cesar de la Fuente-Nunez (cfuente@upenn.edu). 5 This study did not generate new unique reagents.

Test results used for analysis will be provided upon reasonable request.

Clinical samples preparation 

The electrochemical sensors were screen-printed in a three-electrode configuration cell (dimensions: 1.8 x 1.2 cm) on two accessible substrates (i) a qualitative filter paper and (ii) phenolic paper circuit board material. First, specific patterns were wax printed on A4 size filter single A4 size paper, 80 patterns were printed, thus affording 80 disposable ePADs. Following, the screen-printing process was performed in the previously patterned paper using electrically conductive carbon and Ag/AgCl inks (Creative Materials, USA) to fabricate the working/auxiliary electrodes and reference electrodes, respectively. The printed filter paper sheets were then placed in a thermal oven for 30 minutes at 100 °C. The heating process induces 5 the curing step of the conductive tracks and melts the deposited wax layer that then penetrated in the cellulosic structure, forming a 3D hydrophobic barrier around the hydrophilic patterns (electrochemical cell). Finally, the electrochemical paper-based analytical devices (ePADs) were cut with scissors and the backside of the devices was covered with a transparent tape to prevent solution leakage through the device and to add structural integrity. The phenolic paper is a 10 material largely used as a printed circuit board substrate. The boards were washed thoroughly with deionized water and isopropyl alcohol. The screen-printing process on the paper phenolic resin was performed using the same design and dimension reported for the filter paper platform.

The electrochemical circuit board-based devices (eChip) present a rigid substrate and low wettability that dispenses the use of a hydrophobic barrier. After the curing step of printed 15 electrodes, they were cut into small pieces (2 x 2 cm) and a non-conductive layer was applied to delimit the electrode area.

The electrodes were washed with deionized water and cleaned/activated electrochemically by cyclic voltammetry (CV) recorded in sulfuric acid solution (0.1 mol L -1 ) in the potential range Optimization tests 15 We evaluated the main experimental parameters and processes that affect the efficiency of the developed biosensor. For modification steps, both GA and BSA were used at high concentration levels to ensure the complete recovery of the electrode surface providing the best condition to covalently attachment of ACE2 and its stabilization. The formation of permselective membrane was evaluated by using different Nafion concentrations in the range of 0.5 to 3.0 wt%. After the 20 biosensor preparation, we evaluate its response to different concentrations (1 pg mL -1 -10 µg mL -1 ) of angiotensin II (AngII), the natural substrate of ACE2, to verify if the anchoring and stabilization strategies maintain the biological activity of ACE2. To assess the kinetics of interaction between SP and the architecture of the modified electrode, we carried out calibration curves ranging from 1 pg mL -1 to 1 ng mL -1 SP using different times of incubation (from 1-10 25 minutes) to obtain the best analytical response toRAPID1.0. Finally, the need for sample pretreatment of saliva samples was evaluated using 3 different approaches: (i) direct use of raw saliva, (ii) 2 minutes of centrifugation at 10,000 rpm, and (iii) simple dilution of sample 1:1 (v/v) with PBS. We performed this study with saliva samples because it presents greater matrix J o u r n a l P r e -p r o o f complexity (high viscosity and content of proteins, lipids, and other biomolecules that can cause biofouling of the electrodic surface) when compared to NP/OP swab samples.

Cross-reactivity assays were carried out by exposing the sensor to three coronaviruses (MHVmurine hepatitis virus at 10 8 PFU mL -1 , HCoV-OC43human coronavirus OC43 at 10 4 PFU 5 mL -1 , and human coronavirus 229E at 10 7 PFU mL -1 ), and four non-coronavirus viral strains 

Cyclic voltammetry and electrochemical impedimetric spectroscopy measurements are presented as an average of 3 or 7 different replicates for each condition and it is described in each figure caption. Graphs were created and statistical tests conducted in GraphPad Prism 9. 

The New York Times. Coronavirus Map: Tracking the Global Outbreak

Involving Nanocomposite Transducers: Characterization, Architecture Surface and Bio-Sensing

Molecular Interaction and Inhibition of SARS-CoV-2 Binding to the ACE2 Receptor

The Proximal Origin of SARS-CoV-2

Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor

Rapid Detection of SARS-CoV-2 Antibodies Using Electrochemical Impedance-Based Detector

Comparing the Analytical Performance of Three 10 SARS-CoV-2 Molecular Diagnostic Assays

A Narrative Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

ACE2 Cell Biology, Regulation, and Physiological Functions

Advances in Paper-Based Analytical Devices

Electrochemical Paper-Based Analytical Devices: Ten Years of Development

Electrochemical SARS-CoV-2 Sensing at Point-of-Care and Artificial Intelligence for Intelligent COVID-19 Management

Engineered ACE2 Receptor Traps Potently Neutralize SARS-CoV-2. Proc. Natl. Acad. Sci

Structural Models of Human ACE2 Variants with SARS-CoV-2 Spike Protein for Structure-Based Drug Design

Information of Coronavirus (COVID-19) Testing

Coronavirus Antigen Tests: Quick and Cheap, but Too Often Wrong? Science (80-. ). 2020

SARS-CoV-2 RapidPlex: A Graphene-Based Multiplexed Telemedicine Platform for Rapid and Low-Cost COVID-19 Diagnosis and Monitoring

Ultrasensitive, and Quantitative Detection of SARS-CoV-2 Using Antisense Oligonucleotides Directed Electrochemical Biosensor Chip

Ultrasensitive Supersandwich-Type Electrochemical Sensor for SARS-CoV-2 from the Infected COVID-19 Patients Using a Smartphone

Paper-Based Electrochemical Biosensor for Diagnosing COVID-19: Detection of SARS-CoV

CRISPR-Cas12-Based Detection of SARS-CoV-2

Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide 15

Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate Severe Acute Respiratory Syndrome Coronavirus 2 Detection

DNA Nanoscaffold-Based SARS-CoV-2 Detection for COVID-19 Diagnosis

Rapid and Visual Detection of 2019 Novel Coronavirus (SARS-CoV-2) by a Reverse Transcription Loop-Mediated Isothermal Amplification Assay